製品名:Methyl 6-chloro-2-pyridinecarboxylate

IUPAC Name:methyl 6-chloropyridine-2-carboxylate

CAS番号:6636-55-1
分子式:C7H6ClNO2
純度:98%
カタログ番号:CM174006
分子量:171.58

包装単位 有効在庫 価格(USD) 数量
CM174006-100g in stock ƏƩ
CM174006-500g in stock ňƩƅ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:6636-55-1
分子式:C7H6ClNO2
融点:-
SMILESコード:O=C(C1=NC(Cl)=CC=C1)OC
密度:
カタログ番号:CM174006
分子量:171.58
沸点:
MDL番号:MFCD00155391
保管方法:Store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Vorasidenib
Servier presented the latest clinical data on the IDH1/2 inhibitor vorasidenib (AG-881) in the treatment of IDH-mutated diffuse glioma at the 28th Annual Meeting of the Society of Neuro-Oncology (SNO). Blinded independent radiology committee evaluation showed that vorasidenib significantly reduced tumor growth and not only preserved the patient's quality of life, but also stabilized neurocognitive function and controlled epilepsy. Based on these results, the company plans to submit a new drug application for vorasidenib to the U.S. FDA by the end of 2023 for the treatment of IDH-mutated diffuse glioma. Vorasidenib is an oral, brain-penetrating and selective dual inhibitor under development that can inhibit mutated IDH1/2 proteins and is a potential "first-in-class" drug. It has received breakthrough therapy designation from the FDA.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.